Abstract

This conceptual framework discloses, as defensive prior art (CC BY 4.0), a multi-component system for ambient-temperature dried red blood cells (RBCs) that would remove the 1-6 C cold chain and 42-day shelf life constraining transfusion in remote and tropical settings. No experimental recovery, haemolysis, or stability data are generated; every quantitative statement is a cited literature anchor. The system combines (i) intracellular trehalose loading as a vitrification agent, e.g. by transient electroporation (Chen Y 2006); (ii) supercritical-CO2 (scCO2) drying as a surface-tension-free dehydration step, explicitly not a pathogen-inactivation or cell-disruption step; (iii) food-grade bacteriostatic excipients (epsilon-poly-L-lysine, rosmarinic, citric and ascorbic acids) for ambient microbial control; and (iv) an optional, unvalidated perfluorocarbon rehydration medium. Three honesty caveats are stated: the tension between scCO2 as a gentle drying medium and as a known microbicidal/cell-lysing agent is resolved by restricting the process to near-critical, integrity-preserving conditions; the food-grade excipients are flagged as not intravenous-grade, requiring formal parenteral toxicology; and the oxygen-carrier element is downgraded to optional. The dominant unsolved problem is post-rehydration haemolysis, which in the best published work remains above the 0.8% transfusion limit; the system is disclosed as a conceptual route to be tested, with specified validation (24-hour recovery, haemolysis, membrane integrity, ATP/2,3-DPG, and excipient toxicology) required before any use. This prior-art disclosure keeps a cold-chain-free transfusion concept in the public domain. This is a prior-art disclosure, not deployment, regulatory, or clinical guidance.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

Download

Share

COinS